[Problems with immunosuppressive agents in nephropathies with chronic renal failure]

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Context:

• Immunosuppressive treatment is standard for transplant recipients but less established for native kidney diseases with chronic renal insufficiency.
• Recent studies suggest benefits of immunosuppression in native kidney nephropathies.
• Accurate renal histology is crucial for guiding immunosuppressive therapy decisions.

Purpose:

• To review the current evidence and clinical considerations for using immunosuppressive treatment in native kidney diseases with chronic renal insufficiency.
• To discuss the definition of a
• point of no return
• and the challenges in applying it to clinical practice.
• To highlight the importance of individualized treatment approaches.

Summary:

• Nonrandomized studies indicate potential benefits of immunosuppressants like cyclophosphamide in membranous nephropathy and IgA nephropathy with renal insufficiency.
• Modified pharmacokinetics in renal insufficiency necessitate dose reduction and toxicity monitoring for agents like steroids, azathioprine, and mycophenolate mofetil.
• The
• point of no return
• for immunosuppressive therapy in chronic renal failure may be beyond commonly accepted thresholds, requiring a holistic patient evaluation.

Impact:

• Suggests that immunosuppressive therapy can be safely and effectively utilized in select patients with native kidney diseases and chronic renal insufficiency.
• Emphasizes the need for personalized treatment strategies over rigid cutoff values for renal function.
• Provides a framework for clinicians to consider immunosuppression in complex renal cases, balancing potential benefits against risks like infection.